Search Result
Results for "
peroxisomes
" in MedChemExpress (MCE) Product Catalog:
8
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-15372
-
GW6471
Maximum Cited Publications
70 Publications Verification
|
PPAR
Apoptosis
|
Cancer
|
|
GW6471 is a selective peroxisome proliferator-activated receptor α (PPARα) antagonist. GW6471 reduces cancer stem cell viability, proliferation, and spheroid formation. GW6471 induces apoptosis and causes metabolic impairment including energy imbalance. GW6471 can be used for the research of paragangliomas and triple-negative breast cancer .
|
-
-
- HY-17538
-
-
-
- HY-13956
-
|
U 72107
|
PPAR
Ferroptosis
|
Metabolic Disease
Cancer
|
|
Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .
|
-
-
- HY-15655
-
|
|
PPAR
|
Neurological Disease
Metabolic Disease
|
|
GW 1929 is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW 1929 (hydrochloride) has antidiabetic efficacy and neuroprotective potential .
|
-
-
- HY-135849A
-
|
|
Reactive Oxygen Species (ROS)
|
Others
Cancer
|
|
Catalase, Bovine Liver is an enzyme widely found in various organisms, including animals, plants and microorganisms. Catalase, Bovine Liver mainly exists in the peroxisome of cells and is an important antioxidant enzyme. Catalase, Bovine Liver plays an important role in removing ROS and maintaining the balance of redox state. Catalase, Bovine Liver is closely related to the occurrence and development of tumors. Catalase, Bovine Liver has the potential to be used in tumor prevention research .
|
-
-
- HY-N0411
-
|
Provitamin A; beta-Carotene
|
Environmental Pollutants
Endogenous Metabolite
Reactive Oxygen Species (ROS)
Apoptosis
|
Metabolic Disease
Cancer
|
|
β-Carotene (Provitamin A), a carotenoid compound, is a naturally-occurring vitamin A precursor. β-Carotene is a modulator of reactive oxygen species (ROS), with antioxidant and antiinflammatory activities. β-Carotene may serve as an antioxidant or as a prooxidant, depending on its intrinsic properties as well as on the redox potential of the biological environment in which it acts. β-Carotene induces breast cancer cells apoptosis, with anticancer activities .
|
-
-
- HY-19937
-
|
|
PPAR
|
Metabolic Disease
|
|
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
|
-
-
- HY-B1836
-
|
MET-88; Quaterin
|
Mitochondrial Metabolism
|
Cardiovascular Disease
Metabolic Disease
|
|
Meldonium (MET-88) functions as a cardioprotective agent by cpmpetetively inhibiting γ-butyrobetaine hydroxylase (BBOX) and carnitine/organic cation transporter type 2 (OCTN2). Meldonium exhibits IC50 values of 34-62 μM for human recombinant BBOX and an EC50 of 21 μM for human OCTN2. Meldonium is a fatty acid oxidation inhibitor .
|
-
-
- HY-122632
-
|
|
Hedgehog
|
Cancer
|
|
Ciliobrevin D is a cell-permeable, reversible and specific inhibitor of AAA+ ATPase motor cytoplasmic dynein. Ciliobrevin D inhibits Hedgehog (Hh) signaling and primary cilia formation. Ciliobrevin D inhibits dynein-dependent microtubule gliding and ATPase activity in vitro .
|
-
-
- HY-15577
-
|
|
PPAR
|
Cancer
|
|
GSK3787 is a selective and irreversible peroxisome proliferator-activated receptor δ (PPARδ) antagonist with pIC50 of 6.6.
|
-
-
- HY-N0246
-
|
|
LXR
Bacterial
|
Inflammation/Immunology
Cancer
|
|
Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of PPAR-γ. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .
|
-
-
- HY-N0234
-
Bavachinin
Maximum Cited Publications
8 Publications Verification
7-O-Methylbavachin; Bavachinin A
|
Amyloid-β
PPAR
HIF/HIF Prolyl-Hydroxylase
|
Inflammation/Immunology
Cancer
|
|
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC50 value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .
|
-
-
- HY-19937A
-
|
|
PPAR
|
Metabolic Disease
|
|
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
|
-
-
- HY-P2756
-
-
-
- HY-B0664
-
|
Win35833
|
PPAR
|
Metabolic Disease
|
|
Ciprofibrate (Win35833) is a potent peroxisome proliferator and increases the phosphorylation level of the PPARalpha . Ciprofibrate acts as an orally active hypolipidaemic agent and can be used for the research of primary hyperlipidaemias .
|
-
-
- HY-W081067
-
|
HFPO-DA
|
PPAR
|
Infection
|
|
Perfluoro (2-methyl-3-oxahexanoic) acid (HFPO-DA) is an orally active PPARα agonist with an EC50 of 2.1 μM for human PPARα. Perfluoro (2-methyl-3-oxahexanoic) acid induces peroxisome proliferation and increases the levels of proinflammatory mediators. It impairs intestinal barrier function and disrupts cecal flora balance. Perfluoro (2-methyl-3-oxahexanoic) acid is applicable to research related to developmental toxicity, hepatotoxicity and intestinal toxicity .
|
-
-
- HY-A0087
-
|
|
Environmental Pollutants
PPAR
Estrogen Receptor/ERR
Biochemical Assay Reagents
Cytochrome P450
|
Others
|
|
Octocrylene is an organic ultraviolet (UV) filter that absorbs mainly UVB radiation and shorter UVA wavelengths. Octocrylene acts as a partial agonist of PPARγ, which alters the gene transcription profile of lipid metabolism enzymes. In addition, Octocrylene is cytotoxic and genotoxic to human skin fibroblasts and mediates the biosynthesis of estrogens such as estriol in zebrafish larvae, while affecting antioxidant pathways including glutathione transferase and peroxisomes .
|
-
-
- HY-N0411R
-
|
Provitamin A (Standard); beta-Carotene (Standard)
|
Reference Standards
Endogenous Metabolite
Apoptosis
Reactive Oxygen Species (ROS)
|
Metabolic Disease
Cancer
|
|
β-Carotene (Standard) is the analytical standard of β-Carotene. This product is intended for research and analytical applications. β-Carotene (Provitamin A), a carotenoid compound, is a naturally-occurring vitamin A precursor. β-Carotene is a modulator of reactive oxygen species (ROS), with antioxidant and antiinflammatory activities. β-Carotene may serve as an antioxidant or as a prooxidant, depending on its intrinsic properties as well as on the redox potential of the biological environment in which it acts. β-Carotene induces breast cancer cells apoptosis, with anticancer activities .
|
-
-
- HY-153344
-
FX-909
1 Publications Verification
|
PPAR
|
Cancer
|
|
FX-909 is a covalent peroxisome proliferator-activated receptor gamma (PPARG) inverse agonist. FX-909 can be used for the research of cancer .
|
-
-
- HY-N15574
-
|
|
LXR
Bacterial
PPAR
|
Infection
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Saringosterol is an orally active steroid found in Sargassum muticum. Saringosterol is a LXR agonist. Saringosterol can lower cholesterol levels and inhibit the mRNA and protein expression of peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT enhancer-binding protein α (C/EBPα). Saringosterol has anti-obesity, anti-atherosclerosis, anti-Mycobacterium tuberculosis and anti-depressant activities .
|
-
-
- HY-121538
-
CUDA
1 Publications Verification
|
Epoxide Hydrolase
PPAR
|
Cardiovascular Disease
|
|
CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .
|
-
-
- HY-117103
-
|
INT131
|
PPAR
|
Metabolic Disease
|
|
AMG131 (INT131) is a potent non-thiazolidinedione (TZD) selective peroxisome proliferator-activated receptor γ modulator (SPPARM). AMG131 binds to PPARγ within the same binding pocket as the TZDs, but occupies a unique space in the pocket and contacts the receptor at distinct points from the TZDs. AMG131 is promising for research of type-2 diabetes mellitus .
|
-
-
- HY-134377
-
|
ASP0367; MA-0211
|
PPAR
|
Metabolic Disease
|
|
Bocidelpar (ASP0367; MA-0211) is a selective, orally active PPARδ modulator. Bocidelpar activates the PPARδ downstream signaling pathway, upregulates the expression of target genes such as ABCA1 and ACAA2. Bocidelpar then promotes fatty acid oxidation (FAO) and mitochondrial biogenesis, and improves mitochondrial dysfunction. Bocidelpar can improve mitochondrial biogenesis and function in muscle cells. Bocidelpar is mainly used in the study of mitochondrial dysfunction diseases such as primary mitochondrial myopathy (PMM) and Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-130479
-
|
|
Adiponectin Receptor
PPAR
PGC-1α
Sirtuin
AMPK
|
Metabolic Disease
|
|
AdipoR agonist 1 (Compound 112254) is an agonist for adiponectin receptor (AdipoR), which activates the transcriptional regulators like peroxisome proliferator-activated receptors (PPARs), peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α), sirtuin 1 (SIRT1), and adenylate-activated protein kinase (AMPK). AdipoR agonist 1 is utilized in preventive doping research .
|
-
-
- HY-N8122
-
|
|
Akt
|
Cancer
|
|
24-Methylenecycloartanyl ferulate is a γ-oryzanol compound. 24-Methylenecycloartanyl ferulate promotes parvin-beta expression in human breast cancer cells. 24-Methylenecycloartanyl ferulate is a potential ATP-competitive Akt1 inhibitor (EC50= 33.3μM) .
|
-
-
- HY-77278
-
|
|
VD/VDR
Aryl Hydrocarbon Receptor
LXR
PPAR
|
Others
|
|
25-Hydroxytachysterol3 is the metabolite of Vitamin D3 (HY-15398). 25-Hydroxytachysterol3 inhibits the proliferation of epidermal keratinocytes and dermal fibroblasts, stimulates the expression of differentiation- and antioxidant-related genes in keratinocytes. 25-Hydroxytachysterol3 activates vitamin D receptor (VDR) and aryl hydrocarbon receptor (AhR), liver X receptor α/β (LXR α/β) and peroxisome proliferator-activated receptor γ (PPARγ), stimulates the expression of CYP24A1 .
|
-
-
- HY-119964
-
|
|
PPAR
|
Cardiovascular Disease
|
|
Cetaben is a PPARα-independent peroxisome proliferator. Cetaben is a non-fibrate hypolipidemic agent and potently reduces the concentration of cholesterol and triglycerides .
|
-
-
- HY-B1836R
-
|
MET-88 (Standard); Quaterin (Standard)
|
Mitochondrial Metabolism
Reference Standards
|
Cardiovascular Disease
Metabolic Disease
|
|
Meldonium (Standard) is the analytical standard of Meldonium. This product is intended for research and analytical applications. Meldonium (MET-88) functions as a cardioprotective agent by cpmpetetively inhibiting γ-butyrobetaine hydroxylase (BBOX) and carnitine/organic cation transporter type 2 (OCTN2). Mildronate (Meldonium) exhibits IC50 values of 34-62 μM for human recombinant BBOX and an EC50 of 21 μM for human OCTN2. Meldonium is a fatty acid oxidation inhibitor .
|
-
-
- HY-139040
-
|
|
PPAR
|
Metabolic Disease
|
|
2-Tetradecylthio acetic acid is a pan-peroxisome proliferator activated receptor (pan-PPAR) activator. 2-Tetradecylthio acetic acid induces hypolipidemia. 2-Tetradecylthio acetic acid reduces plasma lipids and enhances hepatic fatty acid oxidation in rodents. 2-Tetradecylthio acetic acid increases the expression of genes involved in fatty acid uptake, activation, accumulation, and oxidation .
|
-
-
- HY-168049
-
|
|
PPAR
Akt
|
Metabolic Disease
|
|
ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC50=341 nM; PPAR γ: EC50=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis .
|
-
-
- HY-113820
-
|
|
PPAR
|
Metabolic Disease
|
|
AZD4619 is an orally active, selective peroxisome proliferator-activated receptor α (PPARα) agonist. AZD4619 increases alanine aminotransferase 1 (ALT1) protein expression in a dose-dependent manner in human, but not in rat primary hepatocytes. AZD4619 is a lipid-lowering drug .
|
-
-
- HY-164082
-
|
Clofenapate methyl ester; MCP
|
PPAR
|
Metabolic Disease
Cancer
|
|
Methyl clofenapate (Clofenapate methyl ester; MCP) is a peroxisome proliferator, which can induce hypolipidemia, peroxisome proliferation, and hepatocarcinogenesis .
|
-
-
- HY-14831
-
|
MBX 102; JNJ 39659100
|
PPAR
|
Metabolic Disease
|
|
Arhalofenate (MBX 102) is a selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ, used for the treatment of type 2 diabetes.
|
-
-
- HY-101746
-
|
|
PPAR
|
Metabolic Disease
|
|
GSK376501A is a selective peroxisome proliferator-activated receptor gamma (PPARγ) modulator for the treatment of type 2 diabetes mellitus .
|
-
-
- HY-113631
-
|
|
PPAR
|
Neurological Disease
Metabolic Disease
|
|
Amorfrutin B is a highly potent natural peroxisome proliferation-activated receptor γ (PPARγ) agonist with oral activity with Ki values of 19 nM and EC50 values of 73 nM, respectively. Amorfrutin B has hypoglycemic and neuroprotective activities .
|
-
-
- HY-114739
-
|
|
PPAR
|
Metabolic Disease
|
|
MA-0204 is a potent, highly selective and orally available peroxisome proliferator activated receptor δ (PPARδ) modulator with EC50s of 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ, respectively. Potential treatment for Duchene Muscular Dystrophy (DMD) .
|
-
-
- HY-101676
-
|
NID 525
|
Leukotriene Receptor
PPAR
Cytochrome P450
|
Metabolic Disease
|
|
RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC50s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC50 of appr 60 nM and a potent inhibitor of CYP3A4, with a Ki value of 0.5 µM.
|
-
-
- HY-14728
-
|
R1439; RO0728804
|
PPAR
|
Metabolic Disease
|
|
Aleglitazar (R1439) is a potent dual PPARα/γ agonist, with IC50s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes .
|
-
-
- HY-121538A
-
|
|
Epoxide Hydrolase
PPAR
|
Cardiovascular Disease
|
|
CUDA disodium is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA disodium selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA disodium may be valuable for the research of cardiovascular disease .
|
-
-
- HY-W341997
-
|
|
PPAR
|
Metabolic Disease
|
|
9-Octadecynoic acid is a DNA binding agent with a dissociation constant of 1.8 mM. 9-Octadecynoic acid is also an agonist for peroxisome proliferator-activated receptor γ (PPARγ) .
|
-
-
- HY-U00036A
-
|
LY519818
|
PPAR
|
Metabolic Disease
|
|
Naveglitazar (LY519818) is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models .
|
-
-
- HY-17538S
-
|
|
PGC-1α
Autophagy
|
Metabolic Disease
|
|
ZLN005-d4 is deuterium labeled ZLN005. ZLN005 is a potent activator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) .
|
-
-
- HY-W201317
-
|
|
PPAR
|
Metabolic Disease
|
|
E17241 is an inducer of the expression of ABCA1 that increases the protein levels of ABCA1 in RAW 264.7 macrophages. E17241 is also an agonist of peroxisome proliferator-activated receptors (PPARs ). E17241 decreases plasma glucose levels and body weight in KKAy diabetic mice fed a high-fat and high-glucose (HFHG) diet .
|
-
-
- HY-133777
-
|
|
PPAR
|
Cancer
|
|
Ciprofibrate impurity A is an impurity of Ciprofibrate. Ciprofibrate (Win35833) is a potent peroxisome proliferator, increases the phosphorylation level of the PPARalpha .
|
-
-
- HY-14728S
-
|
Aleglitazar-d2; R1439-d2; RO0728804-d2
|
PPAR
|
Others
|
|
Deutaleglitazar (Aleglitazar-d2) is a agonist of dual peroxisome proliferatory activating receptor (PPARα and PPARγ) .
|
-
-
- HY-13956B
-
|
U 72107 potassium
|
PPAR
Ferroptosis
|
Metabolic Disease
Cancer
|
|
Pioglitazone (U 72107) potassium is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium can be used in diabetes research .
|
-
-
- HY-13956R
-
|
U 72107 (Standard)
|
Reference Standards
PPAR
Ferroptosis
|
Metabolic Disease
Cancer
|
|
Pioglitazone (Standard) is the analytical standard of Pioglitazone. This product is intended for research and analytical applications. Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .
|
-
-
- HY-143862
-
|
|
PPAR
|
Metabolic Disease
|
|
Pparδ agonist 7 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 7 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2019105234A1, compound TM4) .
|
-
-
- HY-N0246R
-
|
|
Reference Standards
LXR
Bacterial
|
Metabolic Disease
Inflammation/Immunology
|
|
Saikosaponin A (Standard) is the analytical standard of Saikosaponin A. This product is intended for research and analytical applications. Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also act as a potential peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, significantly promoting the expression of PPAR-γ. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .
|
-
-
- HY-178447
-
|
|
PPAR
Glutathione Peroxidase
SOD
TNF Receptor
Interleukin Related
NF-κB
|
Infection
Metabolic Disease
Endocrinology
|
|
PPARγ agonist 20 is a potent, orally active PPAR-γ agonist. PPARγ agonist 20 effectively increases antioxidant defenses (SOD, GSH) and reduces lipid peroxidation. PPARγ agonist 20 can upregulate of Pparg, Glut4, and AdipoQ, suppresses of TNF-α, IL-6, and NF-κB p65. PPARγ agonist 20 significantly lowers fasting blood glucose, improving glucose tolerance, and restoring metabolic balance in Streptozotocin (HY-13753)-Nicotinamide (HY-B0150)-induced diabetic rats. PPARγ agonist 20 can be used for the study of type 2 diabetes .
|
-
- HY-17538A
-
|
|
PGC-1α
|
Metabolic Disease
|
|
ZLN005 (hydrochloride) is a peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1α) activator. ZLN005 (hydrochloride) can stimulate the expression of PGC-1α and downstream genes in skeletal muscle cells, improve glucose utilization and fatty acid oxidation. ZLN005 (hydrochloride) can increase the transcription of PGC-1α and downstream genes in skeletal muscle of diabetic db/db mice, increase fat oxidation and improve glucose tolerance, pyruvate tolerance and insulin sensitivity .
|
-
- HY-153982
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ agonist 8 is an agonist of PPARγ. PPARγ agonist 8 induces peroxisome proliferator response element (PPRE)-luciferase activity with an EC50 of 0.2 μM .
|
-
- HY-19227
-
|
|
PPAR
|
Cardiovascular Disease
|
|
BM 170249 is a peroxisome proliferator, particularly in the perivenous region of the central acini in the liver. BM 170249 significantly reduces serum triglyceride and cholesterol levels in rats. BM 170249 strongly induces the activity of key enzymes in the peroxisome fatty acid β-oxidation system (such as acyl-CoA oxidase AOX, multifunctional enzyme PH, and thiolase PT), but leads to decreased activity of catalase and uricase in peroxisome components. BM 170249 could be used in lipid-lowering studies .
|
-
- HY-100189
-
-
- HY-B0664S
-
-
- HY-107333
-
|
|
PPAR
|
Metabolic Disease
|
|
Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with Ki value of 18.0 μM. Cinoxate can be used to study obesity .
|
-
- HY-148083
-
|
|
Drug Metabolite
PPAR
|
Metabolic Disease
|
|
TBBPA-sulfate is metabolite of TBBPA. TBBPA has been reported to enhance adipogenesis by binding with the peroxisome proliferator-activated receptor gamma (PPARγ) .
|
-
- HY-101637
-
|
JT 501
|
PPAR
|
Metabolic Disease
|
|
Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels .
|
-
- HY-19109
-
|
|
Leukotriene Receptor
|
Others
|
|
RG-7152 is a tetrazolyl-substituted leukotriene D4 receptor antagonist that can induce peroxisomal β-oxidation and peroxisome bifunctional enzymes (PBEs) in hepatocytes in various animal models. It has been shown to significantly increase PBE levels and β-oxidation activity in rat and mouse liver homogenates, while smaller effects were observed in guinea pigs and monkeys and no effect in dogs. In vitro studies have also shown that it can induce PBEs comparable to clofibric acid, indicating its potential as a peroxisome proliferator .
|
-
- HY-124907
-
|
OMS-403
|
PPAR
|
Neurological Disease
|
|
AI 3-25755 (OMS-403) is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. AI 3-25755 can be used for research on opioid abuse and smoking cessation .
|
-
- HY-114700
-
|
|
PPAR
|
Metabolic Disease
Inflammation/Immunology
|
|
ZINC08438472 is a potent and selective peroxisome proliferator activated receptors-α (PPAR-α) agonist with an EC50 value of 12.1 nM. ZINC08438472 is promising for research of diabetes, hyperlipidaemia and inflammatory disorders .
|
-
- HY-14831A
-
|
(+)-MBX 102; (+)-JNJ 39659100
|
PPAR
|
Metabolic Disease
|
|
(+)-Arhalofenate ((+)-MBX 102) is the less active enantiomer of Arhalofenate (HY-14831). Arhalofenate is a selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ, used for the treatment of type 2 diabetes .
|
-
- HY-U00036
-
|
LY519818 racemate
|
PPAR
|
Metabolic Disease
|
|
Naveglitazar racemate (LY519818 racemate) is the racemate of Naveglitazar. Naveglitazar is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models .
|
-
- HY-113473
-
|
|
PPAR
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
10-Nitrolinoleic acid is a potent peroxisome proliferator-activated receptor γ (PPARγ) agonist. 10-Nitrolinoleic acid competes with [ 3H]Rosiglitazone for binding to PPAR-γ, with an IC50 of 0.22 μM .
|
-
- HY-128344
-
|
|
PARP
Apoptosis
|
Metabolic Disease
|
|
BR102375 is a non-TZD peroxisome proliferator-activated receptor γ (PPAR γ) full agonist for the treatment of type 2 diabetes, reveals EC50 value of 0.28 μM and Amax ratio of 98% .
|
-
- HY-105325
-
|
|
PPAR
|
Inflammation/Immunology
|
|
SB-219994 is a peroxisome proliferator-activated receptors (PPARs) agonists. SB-219994 can inhibit airway neutrophilia and associated chemoattractants/survival factors. SB-219994 exhibits anti-inflammation effec .
|
-
- HY-120160A
-
|
CP 86325 Sodium
|
PPAR
|
Neurological Disease
Metabolic Disease
|
|
Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective PPAR-γ (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .
|
-
- HY-122083
-
|
|
PPAR
|
Metabolic Disease
|
|
T2384 is a peroxisome proliferator-activated receptor γ (PPARγ) ligand. T2384 also is an orally active antidiabetic agent. T2384 reduces the fasting plasma glucose levels and plasma insulin levels .
|
-
- HY-107333S
-
|
|
Isotope-Labeled Compounds
PPAR
|
Metabolic Disease
|
|
Cinoxate-d3 is deuterium labeled Cinoxate. Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with Ki value of 18.0 μM. Cinoxate can be used to study obesity .
|
-
- HY-108572
-
|
|
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
|
S26948 is a specific peroxisome proliferator-activated receptor γ (PPARγ) modulator (EC50=8.83 nM) with potent antidiabetes and antiatherogenic effects. S26948 is a specific high-affinity agonist for PPARγ .
|
-
- HY-118514
-
|
|
PPAR
|
Metabolic Disease
|
|
CAY10514 is an aromatic of 8(S)-HETE. CAY10514 acts as a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ with IC50 of 0.173 and 0.642 μM, respectively .
|
-
- HY-B0664R
-
|
Win35833 (Standard)
|
PPAR
Reference Standards
|
Metabolic Disease
|
|
Ciprofibrate (Standard) is the analytical standard of Ciprofibrate. This product is intended for research and analytical applications. Ciprofibrate (Win35833) is a potent peroxisome proliferator and increases the phosphorylation level of the PPARalpha . Ciprofibrate acts as an orally active hypolipidaemic agent and can be used for the research of primary hyperlipidaemias .
|
-
- HY-13956C
-
|
(R)-U 72107
|
PPAR
|
Neurological Disease
|
|
(R)-Pioglitazone ((+)-pioglitazone) is the R enantiomer of Pioglitazone (HY-13956). (R)-Pioglitazone is an orally active and selective peroxisome proliferator-activated receptor (PPARγ) agonist with high affinity binding to the PPARγ ligand-binding domain. (R)-Pioglitazone can be used for the research of Alzheimer's disease .
|
-
- HY-19937S1
-
|
|
Isotope-Labeled Compounds
|
Others
|
|
Saroglitazar-d4 is the deuterium-labeled Saroglitazar (HY-19937). Saroglitazar-d4 is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
|
-
- HY-B1419R
-
|
2-Hydroxybenzyl alcohol (Standard); Saligenin (Standard)
|
Drug Intermediate
Reference Standards
|
Others
|
|
Soyasaponin Aa (Standard) is the analytical standard of Soyasaponin Aa. This product is intended for research and analytical applications. Soyasaponin Aa is a soyasaponin that exerts an anti-obesity effect in 3T3-L1 adipocytes through downregulation of peroxisome proliferator-activated receptor γ (PPARγ) .
|
-
- HY-176062
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ modulator-3 (Compound 11) is a peroxisome proliferator-activated receptor γ (PPARγ) modulator with a KD value of 186 nM. PPARγ modulator-3 is promising for research of insulin resistance (IR)-related diseases, such as type 2 diabetes mellitus (T2DM) and metabolic syndrome .
|
-
- HY-115357
-
|
|
PPAR
|
Metabolic Disease
|
|
BMS711939 is a selective agonist for peroxisome proliferator-activated receptor α (PPAR α), with EC50 of 4 nM and 4.5 μM, for human PPARα and human PPARγ. BMS711939 exhibits good pharmacokinetic characters in rats models. BMS711939 increases HDL cholesterol, reduces LDL cholesterol and triglycerides .
|
-
- HY-163443
-
|
|
PPAR
|
Others
|
|
PPAR agonist 4 (Compound 12) is an orally active agonist for peroxisome proliferator-activated receptor (PPAR), which activates PPARα, PPARδ and PPARγ with EC50s of 0.7, 0.7 and 1.8 μM, respectively. PPAR agonist 4 exhibits anti-liver fibrosis efficacy .
|
-
- HY-155704
-
|
|
PPAR
|
Others
|
|
DPP-IV-IN-5 is isolated from the fruits of Lycium barbarum. DPP-IV-IN-5 exerts moderate agonistic activities for peroxisome proliferator-activated receptor (PPARγ) with EC50 values of 10.09 - 44.26 μM and also presents inhibitory activity on dipeptidyl peptidase-4 (DPPIV) with an IC50 value of 47.13 μM .
|
-
- HY-121538S
-
|
|
Isotope-Labeled Compounds
Epoxide Hydrolase
PPAR
|
Cardiovascular Disease
|
|
CUDA-d11 is deuterium labeled CUDA (HY-121538). CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .
|
-
- HY-N1990R
-
|
|
Reference Standards
PPAR
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Gypenoside XLIX (Standard) is the analytical standard of Gypenoside XLIX. This product is intended for research and analytical applications. Gypenoside XLIX, a dammarane-type glycoside, is a prominent component of G. pentaphyllum. Gypenoside XLIX is a selective peroxisome proliferator-activated receptor (PPAR)-alpha activator and inhibits cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) overexpression and hyperactivity in human endothelial cells .
|
-
- HY-106181A
-
|
R-106056 hydrochloride
|
PPAR
|
Metabolic Disease
|
|
Rivoglitazone hydrochloride (R-106056 hydrochloride) is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist. Rivoglitazone hydrochloride (R-106056 hydrochloride) exerts its anti-diabetic effect by activating PPARγ to regulate the expression of a large number of genes related to lipid and glucose metabolism. Rivoglitazone hydrochloride (R-106056 hydrochloride) can be used to study insulin secretion and insulin resistance in animal models of diabetes .
|
-
- HY-W027751R
-
|
|
Drug Intermediate
Reference Standards
|
Others
|
|
Gypenoside XLIX (Standard) is the analytical standard of Gypenoside XLIX. This product is intended for research and analytical applications. Gypenoside XLIX, a dammarane-type glycoside, is a prominent component of G. pentaphyllum. Gypenoside XLIX is a selective peroxisome proliferator-activated receptor (PPAR)-alpha activator and inhibits cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) overexpression and hyperactivity in human endothelial cells .
|
-
- HY-117103A
-
|
INT131 benzenesulfonate
|
PPAR
|
Metabolic Disease
|
|
AMG131 (INT131) (benzenesulfonate) is a potent non-thiazolidinedione (TZD) selective peroxisome proliferator-activated receptor γ modulator (SPPARM). AMG131 (benzenesulfonate) binds to PPARγ within the same binding pocket as the TZDs, but occupies a unique space in the pocket and contacts the receptor at distinct points from the TZDs. AMG131 (benzenesulfonate) is promising for research of type-2 diabetes mellitus .
|
-
- HY-110022
-
|
|
PPAR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis and shows anti-inflammatory potential .
|
-
- HY-143863
-
|
|
PPAR
|
Metabolic Disease
|
|
Pparδ agonist 8 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 8 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2021169769A1, compound TM2) .
|
-
- HY-117459
-
|
|
PPAR
|
Metabolic Disease
|
|
E-3030 free acid is a potent dual activator of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma, exhibiting significant antidiabetic and lipid-modulating effects. E-3030 decreases blood glucose, triglyceride, non-esterified fatty acids, and insulin levels, while increasing blood adiponectin levels. E-3030 improves glucose tolerance and shows remarkable triglyceride- and non-high-density lipoprotein cholesterol-lowering effects in animal models.
|
-
- HY-171793
-
|
|
PPAR
|
Metabolic Disease
|
|
DN-108, a thiazolidinedione derivative, is an orally active peroxisome proliferator-activated receptor γ (PPARγ) agonist with antidiabetic effects. DN-108 improves hyperglycemia, hypertriglyceridemia and hyperinsulinemia in diabetic mouse models. DN-108 enhances tissue glucose uptake (e.g., increasing 2-deoxyglucose uptake in L6 muscle cells) and inhibits fatty acid synthase activity. DN-108 is promising for research of type 2 diabetes .
|
-
- HY-121888
-
|
|
PPAR
|
Metabolic Disease
|
|
20-HEPE is a metabolite of eicosapentaenoic acid formed by ω-oxidation of EPA by cytochrome P450 (CYP) ω-oxidases, including human CYP4F3B. At 10 μM, it activates peroxisome proliferator-activated receptor α (PPARα) in COS-7 cells expressing a luciferase reporter gene. 20-HEPE also activates mouse transient receptor potential vanilloid receptor 1 (mTRPV1) in vitro but lacks analgesic activity in rats.
|
-
- HY-139040R
-
|
Tetradecylthioacetic acid (Standard)
|
PPAR
Reference Standards
|
Metabolic Disease
|
|
2-(Tetradecylthio)acetic acid (Standard) is the analytical standard of 2-(Tetradecylthio)acetic acid. This product is intended for research and analytical applications. 2-Tetradecylthio acetic acid is a pan-peroxisome proliferator activated receptor (pan-PPAR) activator. 2-Tetradecylthio acetic acid induces hypolipidemia. 2-Tetradecylthio acetic acid reduces plasma lipids and enhances hepatic fatty acid oxidation in rodents. 2-Tetradecylthio acetic acid increases the expression of genes involved in fatty acid uptake, activation, accumulation, and oxidation .
|
-
- HY-W654296
-
|
|
Isotope-Labeled Compounds
PPAR
Cytochrome P450
Biochemical Assay Reagents
Estrogen Receptor/ERR
|
Others
|
|
Octocrylene- 13C3 is the 13C-labeled Octocrylene (HY-A0087). Octocrylene is an organic ultraviolet (UV) filter that absorbs mainly UVB radiation and shorter UVA wavelengths. Octocrylene acts as a partial agonist of PPARγ, which alters the gene transcription profile of lipid metabolism enzymes. In addition, Octocrylene is cytotoxic and genotoxic to human skin fibroblasts and mediates the biosynthesis of estrogens such as estriol in zebrafish larvae, while affecting antioxidant pathways including glutathione transferase and peroxisomes .
|
-
- HY-N11507
-
|
TKV
|
PPAR
|
Metabolic Disease
|
|
Tibesaikosaponin V (TKV) is a triterpene diglycoside, which can be isolated from the methanol extract of the roots of Bupleurum chinense DC.. Tibesaikosaponin V inhibits lipid accumulation and triacylglycerol content occurred without cytotoxicity to adipocytes. Tibesaikosaponin V suppresses the mRNA expression of nuclear transcription factors, such as peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα). Tibesaikosaponin V inhibits 3T3-L1 preadipocyte differentiation. Tibesaikosaponin V can be used fro research of obesity and its associated metabolic disorders .
|
-
- HY-N0234R
-
|
7-O-Methylbavachin (Standard); Bavachinin A (Standard)
|
Amyloid-β
Reference Standards
PPAR
HIF/HIF Prolyl-Hydroxylase
|
Inflammation/Immunology
|
|
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC50 value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .
|
-
- HY-175392
-
|
|
PROTACs
Epoxide Hydrolase
|
Metabolic Disease
Inflammation/Immunology
|
|
PROTAC sEH-degrader-3 (Compound 1a) is a targeted sEH PROTAC degrader that can selectively degrade sEH in the cytosol without affecting sEH in peroxisomes. PROTAC sEH-degrader-3 degrades sEH through a CRBN-dependent lysosomal pathway rather than the proteasome, with an IC50 of 0.8 nM against hsEH. PROTAC sEH-degrader-3 can inhibit endoplasmic reticulum stress and can be used in the research of inflammation, metabolic diseases, and other diseases related to endoplasmic reticulum stress. (Pink: sEH inhibitor (HY-114266); Black: Linker (HY-W008352); Blue: E3 Ligase Ligand (HY-14658)) .
|
-
- HY-B1520
-
|
Aluminum clofibrate
|
PPAR
|
Cancer
|
|
Aluminium clofibrate is an orally active peroxisome proliferator. Aluminium clofibrate increases peroxisomal β-oxidation enzyme activities, elevates catalase. Aluminium clofibrate can be used in the research of cancer .
|
-
- HY-106266C
-
|
(R)-Carfloglitazar
|
Drug Isomer
|
Metabolic Disease
|
|
(R)-Chiglitazar is the enantiomer of Chiglitazar (HY-106266). Chiglitazar is a peroxisome PPAR agonist that can be used for the study of type 2 diabetes .
|
-
- HY-185128
-
-
- HY-176029
-
|
NAPE(16:0/16:0/18:1); N-Oleoyl-1,2-dipalmitoyl-3-PE
|
Drug Intermediate
|
Neurological Disease
Inflammation/Immunology
|
|
N-Oleoyl-DPPE ammonium is an N-acylphosphatidylethanolamine (NAPE). N-Oleoyl-DPPE ammonium is a biosynthetic precursor of oleoylethanolamide (OEA), an endocannabinoid derivative and peroxisome proliferator-activated receptor α (PPARα) agonist. N-Oleoyl-DPPE ammonium can be used in the study of neuroinflammation and alcohol abuse .
|
-
- HY-182619
-
|
|
PPAR
|
Cancer
|
|
PPARα/δ antagonist-1 is an orally active, highly selective dual antagonist of PPARα/δ, with IC50 values of 0.113 μM and 0.025 μM against human PPARα and PPARδ, respectively. PPARα/δ antagonist-1 exhibits an excellent in vitro activity profile and preliminary efficacy in mouse tumor models. PPARα/δ antagonist-1 can be used in studies related to cancers (melanoma metastasis, ovarian cancer) .
|
-
- HY-183318
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARα/δ agonist 4 is a potent orally active and selective dual peroxisome proliferator-activated receptor (PPAR) α/δ agonist with EC50s of 0.36 and 1.31 nM, respectively. PPARα/δ agonist 4 exhibits >123-fold selectivity over PPARγ (EC50 = 160.84 nM). PPARα/δ agonist 4 upregulates expression of downstream fatty acid oxidation genes PDK4, CPT1A, and ACADVL. PPARα/δ agonist 4 can be used for the research of metabolic dysfunction-associated steatohepatitis .
|
-
- HY-101676R
-
|
NID 525 (Standard)
|
Leukotriene Receptor
Reference Standards
PPAR
Cytochrome P450
|
Metabolic Disease
|
|
RG-12525 (Standard) is the analytical standard of RG-12525 (HY-101676). This product is intended for research and analytical applications. RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC50s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC50 of appr 60 nM and a potent inhibitor of CYP3A4, with a Ki value of 0.5 μM.
|
-
- HY-N1472
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
PPAR
GSK-3
Tau Protein
Ras
TGF-β Receptor
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Levistolide A is an apoptosis inducer and a PEDV virus inhibitor. Levistolide A can induce apoptosis in colon cancer cells and suppress the replication of porcine epidemic diarrhea virus (PEDV) by promoting ROS generation. Levistolide A activates peroxisome proliferator-activated receptor γ (PPARγ) in N2a/APP695swe cells and reduces excessive phosphorylation of tau through the GSK3α/β pathway, improving symptoms in Alzheimer’s mice. Levistolide A improves kidney damage in 5/6 nephrectomy (Nx) mice by inhibiting the RAS,TGF-β1/Smad, and MAPK pathways .
|
-
- HY-124399
-
|
|
Endogenous Metabolite
PPAR
|
Metabolic Disease
|
|
Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating lipid and glucose metabolism, and oleoylethanolamide (OEA) is a natural ligand for PPARα. N-Octadecyl-N'-propyl-sulfamide is an analog of OEA and a potent activator of PPARα, with selective binding affinity for PPARα (EC50=100 nM, compared to 120 nM for OEA). N-Octadecyl-N'-propyl-sulfamide (10 mg/kg; ip) inhibits food intake and reduces body weight gain in rats. At a dose of 1 mg/kg, N-Octadecyl-N'-propyl-sulfamide induces satiety, thereby reducing food intake, body weight, and plasma triglyceride concentrations in free-feeding Wistar rats and obese Zucker (fa/fa) rats.
|
-
- HY-N18020
-
-
- HY-181894
-
-
- HY-171895
-
|
12-Nitro-9-cis,12-cis-octadecadienoic acid
|
PPAR
Interleukin Related
NF-κB
TNF Receptor
|
Inflammation/Immunology
|
|
12-Nitrolinoleate (12-Nitro-9-cis,12-cis-octadecadienoic acid) is an activator for peroxisome proliferator-activated receptor γ (PPARγ). 12-Nitrolinoleate is a nitrated form of linoleic acid. 12-Nitrolinoleate can be formed upon exposure to acidified nitrate and found in human red blood cells and plasma. 12-Nitrolinoleate can activate PPARγ-dependent gene expression in MCF-7 cells expressing PPARγ with an EC50 = 0.045 μM. 12-Nitrolinoleate is able to inhibit LPS (HY-D1056)-induced NF-κB transcription in RAW 264.7 cells. 12-Nitrolinoleate can inhibit IL-6, TNF-α and CCL2 induced by LPS .
|
-
- HY-180952
-
|
|
Drug Metabolite
COX
PPAR
NF-κB
p38 MAPK
|
Inflammation/Immunology
|
|
Zaltoprofen sulfoxide (Compound M2) is the main metabolite of Zaltoprofen (HY-B0619). Zaltoprofen sulfoxide is an efficient and selective COX-2 inhibitor (IC50 = 45.38 nM) and a PPAR-γ activator. Zaltoprofen sulfoxide effectively inhibits NF-κB and MAPK inflammatory signaling pathways and alleviates acute lung injury induced by LPS (HY-D1056B3). Zaltoprofen sulfoxide can be used for the study of acute lung injury .
|
-
- HY-181896S
-
|
|
PPAR
|
Inflammation/Immunology
|
|
PPARγ agonist-23 (Compound 9) is an orally active PPARγ agonist with an EC50 of 0.32 μM. PPARγ agonist-23 improves hepatic triglyceride levels, reduces scores of steatosis and hepatocellular ballooning, and decreases the total activity score of non-alcoholic steatohepatitis (NASH). PPARγ agonist-23 can be used for the research of non-alcoholic steatohepatitis .
|
-
- HY-180398
-
|
|
PPAR
PGC-1α
|
Metabolic Disease
|
|
PA-082 is a selective PPAR-γ modulator that functions as a partial agonist. PA-082 causes partial recruitment of SRC1, TIF2, SRC3 and full recruitment of PGC1-α to PPAR-γ ligand-binding domain. PA-082 prevents triglyceride accumulation during de novo adipogenesis and antagonizes Rosiglitazone (HY-17386)-induced lipid accumulation. PA-082 potentiates insulin-stimulated glucose uptake in adipocytes and protects against TNFα-induced insulin resistance. PA-082 can be used for the research of type 2 diabetes .
|
-
- HY-173432
-
|
|
ACSL Family
Ferroptosis
|
Neurological Disease
Cancer
|
|
LIBX-A401 is a selective long-chain acyl-CoA synthetase 4 (ACSL4) inhibitor with a human IC50 values of 0.38 μM and a Kd of 0.72 μM. LIBX-A401 binds to ACSL4 in an ATP-dependent manner, stabilizes the C-terminal domain, alters the fatty acid gate region, and interacts with residues A329 and Q302 within the fatty acid binding site. LIBX-A401 exhibits anti-ferroptosis properties in cells. LIBX-A401 can be used for the researches of cancer and parkinson's disease .
|
-
- HY-21191
-
|
PFBS
|
Biochemical Assay Reagents
PPAR
Reactive Oxygen Species (ROS)
|
Metabolic Disease
|
|
Perfluorobutanesulfonic acid (PFBS) is a short-chain perfluoroalkyl substance and the main replacement for perfluorooctanesulfonic acid. Perfluorobutanesulfonic acid induces fat accumulation in human HepG2 hepatoma cells. Perfluorobutanesulfonic acid promotes lipid accumulation by activating PPARγ pathway and triggering oxidative stress, endoplasmic reticulum stress and calcium dyshomeostasis. Perfluorobutanesulfonic acid impairs reproduction and causes developmental disorders in offspring of Caenorhabditis elegans. Perfluorobutanesulfonic acid disrupts pancreatic organogenesis and lipid homeostasis in zebrafish embryos. Perfluorobutanesulfonic acid can be used in environmental toxicology, lipid metabolism and developmental toxicity studies .
|
-
- HY-182046
-
|
|
MNK
PPAR
Eukaryotic Initiation Factor (eIF)
Stearoyl-CoA Desaturase (SCD)
|
Metabolic Disease
|
|
HD202A is an orally active, selective dual inhibitor of MNK1/MNK2 (with IC50 values of 6.09 nM and 8.06 nM, and Kd values of 1.913 μM and 5.244 μM, respectively) that inhibits the MNK-eIF4E signaling pathway. By downregulating perilipin 2 and SCD1, while upregulating adipose triglyceride lipase and PPARγ coactivator 1α, HD202A enhances mitochondrial fatty acid oxidation and redox homeostasis. HD202A effectively suppresses body weight gain, hepatic lipid accumulation and elevation of serum lipids, significantly improves glucose tolerance and insulin sensitivity of the organism, and ameliorates inflammatory features. With these comprehensive pharmacological activities, HD202A exhibits great application potential in studies of metabolic dysfunction-associated steatotic liver disease .
|
-
- HY-112247
-
|
|
PPAR
TGF-beta/Smad
|
Metabolic Disease
Inflammation/Immunology
|
|
SR 16832 is a dual-site covalent, orthosteric and allosteric PPARγ antagonist. SR 16832 activates the TGF-β signaling pathway and upregulates the expression of Vimentin and Fibronectin (Fibronectin). SR 16832 is toxic to bronchial epithelium. SR 16832 can be used in research related to type 2 diabetes and pulmonary fibrosis .
|
-
- HY-181233
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ agonist-22 is a PPARγ agonist. PPARγ agonist-22 promotes cellular glucose uptake. PPARγ agonist-22 reduces lipid accumulation in adipocytes. PPARγ agonist-22 can be used in the research of type 2 diabetes .
|
-
- HY-116028
-
|
15-Deoxy-Δ12,14-PGD2
|
Endogenous Metabolite
Prostaglandin Receptor
PPAR
Src
|
Cardiovascular Disease
|
|
15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2), a metabolite of PGD2 (HY-101988), is an agonist of prostaglandin receptor 2 (DP2). 15-deoxy-Δ12,14-Prostaglandin D2 binds to DP2 (Ki=50 nM) and induces eosinophil activation (EC50=8 nM). 15-deoxy-Δ12,14-Prostaglandin D2 also stimulates the recruitment of steroid receptor coactivator-1 (SRC-1) to peroxisome proliferator-activated receptor γ (PPARγ), inducing PPARγ-mediated transcription. 15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2) is cytotoxic to L1210 murine leukemia cells (IC50=0.3 μg/ml) and inhibits ADP-induced platelet aggregation (IC50=320 ng/mL).
|
-
- HY-126956
-
|
|
Reactive Oxygen Species (ROS)
MMP
Collagen
PPAR
DNA/RNA Synthesis
Apoptosis
Caspase
|
Metabolic Disease
Inflammation/Immunology
|
|
Porphyra 334 is a carnosine-like amino acid and a natural photoprotective agent and antioxidant. Porphyra-334 exerts its photoprotective effects by scavenging ROS, inhibiting the expression and activity of MMP-1/8, and promoting the synthesis of collagen and elastin. Porphyra 334 effectively inhibits linoleic acid oxidation induced by alkyl radicals (AAPH) and singlet oxygen. Porphyra 334 has anti-obesity potential by inhibiting the expression of PPARγ2 and C/EBPα. Porphyra 334 protects cells against UV-induced DNA damage and apoptosis by inhibiting the activation of caspase-3 .
|
-
- HY-133668
-
|
|
Drug Metabolite
Cytochrome P450
PPAR
|
Endocrinology
Cancer
|
|
Monoethyl phthalate is an orally active PDX-1 activator and the major hydrolytic metabolite of Diethyl phthalate (HY-Y0284) in vivo, with reproductive toxicity. Monoethyl phthalate targets aromatase (aromatase/CYP19A1) and PPAR to induce cell proliferation. The plasma protein binding rate of Monoethyl phthalate in rats and humans is lower than that of Diethyl phthalate. It exhibits significant enterohepatic circulation in rats and mainly accumulates in liver tissues. Monoethyl phthalate shows no estrogenic activity in estrogen-dependent human breast cancer cells. Monoethyl phthalate can be used in studies of reproductive toxicity and related environmental endocrine disruption mechanisms .
|
-
- HY-W275295
-
-
- HY-P11589
-
|
|
PPAR
Reactive Oxygen Species (ROS)
Keap1-Nrf2
|
Metabolic Disease
|
|
PIISVYWK is an orally active PPARγ Inhibitor, heme oxygenase-1 Activator, and Nrf2 Activator. PIISVYWK mediates activity via the HO-1/Nrf2 pathway, ameliorates oxidative stress, reduces inflammation, and mediates anti-obesity activity. PIISVYWK can be used for the research of obesity .
|
-
- HY-N18066
-
|
|
Drug Derivative
Acyltransferase
NF-κB
PPAR
Fatty Acid Synthase (FASN)
Keap1-Nrf2
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
Esculeogenin A is the sapogenol of tomato saponin Esculeoside A (HY-N18067). Esculeogenin A is an orally active hepatoprotective, hypolipidemic, and antioxidant agent. Esculeogenin A regulates molecular targets like PPARα, SREBP1, Nrf2, NF-κB, ACAT1/ACAT2 to promote hepatic fatty acid oxidation, suppress de novo lipogenesis, enhance antioxidant defense, and inhibit inflammation. Esculeogenin A improves liver function, alleviates hyperlipidemia, and inhibits hepatic steatosis and foam cell formation, preventing nonalcoholic fatty liver disease in high-fat-diet-fed rats and reducing atherosclerotic lesions in apoE-deficient mice. Esculeogenin A can be used for the research of nonalcoholic fatty liver disease, atherosclerosis, and hyperlipidemia .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P11589
-
|
|
PPAR
Reactive Oxygen Species (ROS)
Keap1-Nrf2
|
Metabolic Disease
|
|
PIISVYWK is an orally active PPARγ Inhibitor, heme oxygenase-1 Activator, and Nrf2 Activator. PIISVYWK mediates activity via the HO-1/Nrf2 pathway, ameliorates oxidative stress, reduces inflammation, and mediates anti-obesity activity. PIISVYWK can be used for the research of obesity .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N0411
-
-
-
- HY-N0246
-
-
-
- HY-N0234
-
-
-
- HY-133668
-
|
|
Other disease
Disease markers
Endogenous metabolite
|
Drug Metabolite
Cytochrome P450
PPAR
|
|
Monoethyl phthalate is an orally active PDX-1 activator and the major hydrolytic metabolite of Diethyl phthalate (HY-Y0284) in vivo, with reproductive toxicity. Monoethyl phthalate targets aromatase (aromatase/CYP19A1) and PPAR to induce cell proliferation. The plasma protein binding rate of Monoethyl phthalate in rats and humans is lower than that of Diethyl phthalate. It exhibits significant enterohepatic circulation in rats and mainly accumulates in liver tissues. Monoethyl phthalate shows no estrogenic activity in estrogen-dependent human breast cancer cells. Monoethyl phthalate can be used in studies of reproductive toxicity and related environmental endocrine disruption mechanisms .
|
-
-
- HY-N0411R
-
-
-
- HY-N15574
-
-
-
- HY-N1472
-
-
-
- HY-126956
-
-
-
- HY-N8122
-
-
-
- HY-113631
-
-
-
- HY-W341997
-
-
-
- HY-13956R
-
|
U 72107 (Standard)
|
Human Gut Microbiota Metabolites
Endogenous metabolite
Source Classification
|
Reference Standards
PPAR
Ferroptosis
|
|
Pioglitazone (Standard) is the analytical standard of Pioglitazone. This product is intended for research and analytical applications. Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .
|
-
-
- HY-N0246R
-
-
-
- HY-B1419R
-
-
-
- HY-155704
-
|
|
Lycium barbarum L.
Phenols
Polyphenols
Solanaceae
Plants
Source Classification
|
PPAR
|
|
DPP-IV-IN-5 is isolated from the fruits of Lycium barbarum. DPP-IV-IN-5 exerts moderate agonistic activities for peroxisome proliferator-activated receptor (PPARγ) with EC50 values of 10.09 - 44.26 μM and also presents inhibitory activity on dipeptidyl peptidase-4 (DPPIV) with an IC50 value of 47.13 μM .
|
-
-
- HY-N1990R
-
-
-
- HY-N11507
-
|
TKV
|
Triterpenes
Sonchus asper (L.) Hill
Terpenoids
Plants
Umbelliferae
Source Classification
|
PPAR
|
|
Tibesaikosaponin V (TKV) is a triterpene diglycoside, which can be isolated from the methanol extract of the roots of Bupleurum chinense DC.. Tibesaikosaponin V inhibits lipid accumulation and triacylglycerol content occurred without cytotoxicity to adipocytes. Tibesaikosaponin V suppresses the mRNA expression of nuclear transcription factors, such as peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα). Tibesaikosaponin V inhibits 3T3-L1 preadipocyte differentiation. Tibesaikosaponin V can be used fro research of obesity and its associated metabolic disorders .
|
-
-
- HY-N0234R
-
-
-
- HY-N18020
-
-
-
- HY-N18066
-
|
|
Structural Classification
Solanum lycopersicum L.
Solanaceae
Plants
Steroids
Source Classification
|
Drug Derivative
Acyltransferase
NF-κB
PPAR
Fatty Acid Synthase (FASN)
Keap1-Nrf2
|
|
Esculeogenin A is the sapogenol of tomato saponin Esculeoside A (HY-N18067). Esculeogenin A is an orally active hepatoprotective, hypolipidemic, and antioxidant agent. Esculeogenin A regulates molecular targets like PPARα, SREBP1, Nrf2, NF-κB, ACAT1/ACAT2 to promote hepatic fatty acid oxidation, suppress de novo lipogenesis, enhance antioxidant defense, and inhibit inflammation. Esculeogenin A improves liver function, alleviates hyperlipidemia, and inhibits hepatic steatosis and foam cell formation, preventing nonalcoholic fatty liver disease in high-fat-diet-fed rats and reducing atherosclerotic lesions in apoE-deficient mice. Esculeogenin A can be used for the research of nonalcoholic fatty liver disease, atherosclerosis, and hyperlipidemia .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-17538S
-
|
|
|
ZLN005-d4 is deuterium labeled ZLN005. ZLN005 is a potent activator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) .
|
-
-
- HY-14728S
-
|
|
|
Deutaleglitazar (Aleglitazar-d2) is a agonist of dual peroxisome proliferatory activating receptor (PPARα and PPARγ) .
|
-
-
- HY-B0664S
-
|
|
|
Ciprofibrate-d6 is deuterium labeled Ciprofibrate. Ciprofibrate (Win35833) is a potent peroxisome proliferator, increases the phosphorylation level of the PPARalpha .
|
-
-
- HY-107333S
-
|
|
|
Cinoxate-d3 is deuterium labeled Cinoxate. Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with Ki value of 18.0 μM. Cinoxate can be used to study obesity .
|
-
-
- HY-19937S1
-
|
|
|
Saroglitazar-d4 is the deuterium-labeled Saroglitazar (HY-19937). Saroglitazar-d4 is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
|
-
-
- HY-121538S
-
|
|
|
CUDA-d11 is deuterium labeled CUDA (HY-121538). CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .
|
-
-
- HY-W654296
-
|
|
|
Octocrylene- 13C3 is the 13C-labeled Octocrylene (HY-A0087). Octocrylene is an organic ultraviolet (UV) filter that absorbs mainly UVB radiation and shorter UVA wavelengths. Octocrylene acts as a partial agonist of PPARγ, which alters the gene transcription profile of lipid metabolism enzymes. In addition, Octocrylene is cytotoxic and genotoxic to human skin fibroblasts and mediates the biosynthesis of estrogens such as estriol in zebrafish larvae, while affecting antioxidant pathways including glutathione transferase and peroxisomes .
|
-
-
- HY-181896S
-
|
|
|
PPARγ agonist-23 (Compound 9) is an orally active PPARγ agonist with an EC50 of 0.32 μM. PPARγ agonist-23 improves hepatic triglyceride levels, reduces scores of steatosis and hepatocellular ballooning, and decreases the total activity score of non-alcoholic steatohepatitis (NASH). PPARγ agonist-23 can be used for the research of non-alcoholic steatohepatitis .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: